193 related articles for article (PubMed ID: 37810255)
1. Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration.
Wei-Zhang S; Cui B; Xing M; Liu J; Guo Y; He K; Bai T; Dong X; Lei Y; Zhou W; Zhou H; Liu S; Wang X; Zhou D; Yan H
iScience; 2023 Oct; 26(10):107939. PubMed ID: 37810255
[TBL] [Abstract][Full Text] [Related]
2. A Hypoxia-Regulated Retinal Pigment Epithelium-Specific Gene Therapy Vector Reduces Choroidal Neovascularization in a Mouse Model.
Yuan Y; Kong W; Liu XM; Shi GH
Curr Gene Ther; 2022; 22(5):417-426. PubMed ID: 35382718
[TBL] [Abstract][Full Text] [Related]
3. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
Gelfman CM; Grishanin R; Bender KO; Nguyen A; Greengard J; Sharma P; Nieves J; Kiss S; Gasmi M
J Ocul Pharmacol Ther; 2021 Apr; 37(3):181-190. PubMed ID: 33835848
[TBL] [Abstract][Full Text] [Related]
5. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
6. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.
Holekamp NM; Bouck N; Volpert O
Am J Ophthalmol; 2002 Aug; 134(2):220-7. PubMed ID: 12140029
[TBL] [Abstract][Full Text] [Related]
7. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.
Cashman SM; Ramo K; Kumar-Singh R
PLoS One; 2011 Apr; 6(4):e19078. PubMed ID: 21552568
[TBL] [Abstract][Full Text] [Related]
8. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
[TBL] [Abstract][Full Text] [Related]
10. Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.
Lambert NG; Zhang X; Rai RR; Uehara H; Choi S; Carroll LS; Das SK; Cahoon JM; Kirk BH; Bentley BM; Ambati BK
Exp Eye Res; 2016 Apr; 145():248-257. PubMed ID: 26775053
[TBL] [Abstract][Full Text] [Related]
11. Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration.
Li W; Dong L; Ma M; Hu B; Lu Z; Liu X; Liu J; Li X
Drug Des Devel Ther; 2016; 10():3415-3423. PubMed ID: 27799741
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for age-related macular degeneration.
Moore NA; Bracha P; Hussain RM; Morral N; Ciulla TA
Expert Opin Biol Ther; 2017 Oct; 17(10):1235-1244. PubMed ID: 28726562
[TBL] [Abstract][Full Text] [Related]
14. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD.
Li L; Zhu M; Wu W; Qin B; Gu J; Tu Y; Chen J; Liu D; Shi Y; Liu X; Sang A; Ding D
J Cell Physiol; 2020 Feb; 235(2):1259-1273. PubMed ID: 31270802
[TBL] [Abstract][Full Text] [Related]
15. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD).
Patel P; Sheth V
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070899
[TBL] [Abstract][Full Text] [Related]
16. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization.
Li Y; Liu X; Zhou T; Kelley MR; Edwards P; Gao H; Qiao X
Redox Biol; 2014; 2():485-94. PubMed ID: 24624338
[TBL] [Abstract][Full Text] [Related]
18. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration.
Bhutto IA; McLeod DS; Hasegawa T; Kim SY; Merges C; Tong P; Lutty GA
Exp Eye Res; 2006 Jan; 82(1):99-110. PubMed ID: 16019000
[TBL] [Abstract][Full Text] [Related]
19. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
[TBL] [Abstract][Full Text] [Related]
20. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
